Why companies are rushing to flatter Trump
By 
Phillip Broadwith2025-03-11T09:50:00
Pharma firms are among many pausing diversity programmes and promising domestic investment
This article originally appeared in the Industry Brief newsletter. Subscribe for free for weekly insights in your inbox.
US President Donald Trump’s executive order halting funding for all diversity, equity and inclusion (DEI) programmes and activities has caused havoc among the federally funded institutions it applies to. However, it has also prompted a wide range of companies, including pharmaceutical multinational GSK, to announce reviews, pauses and revisions of their own DEI commitments.